{"disease":{"id":"solid-tumors-and-lymphomas","name":"solid tumors and lymphomas"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03172936","title":"Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":106,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02392611","title":"Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Gilead Sciences","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}